Strategic partnerships Trinity Biotech is actively pursuing collaborations, exemplified by the March 2026 agreement with the University at Buffalo to commercialize novel Sjögren's syndrome biomarkers. This indicates openness to co-development and joint go-to-market activities that can be leveraged for joint ventures, licensing, or distribution partnerships in diagnostics.

Diabetes focus The company is investing in next-generation diabetes management solutions, including a CGM+ platform and wearable biosensors, signaling opportunities to offer integrated analytics, data services, and complementary diagnostic components to diabetes care providers and payer networks.

Strategic funding Securing $5 million in additional term-loan funding and a solid revenue base (50–100 million) suggests capacity for incremental investment in sales and field expansion, making a compelling case for channel partners and regional distributors to accelerate market reach.

Global leadership With leadership observed at industry events (ATTD 2026, World Health Expo) and strengthened Brazilian commercial leadership, there is a pattern of prioritizing global market access. This presents opportunities to position complementary products, regulatory and market-entry services for regions like Latin America, Europe, and Asia.

Platform integrations The CGM+ initiative and integration of AI-native analytics imply a need for interoperable data ecosystems. Potential sales angles include selling integration services, cloud-based data platforms, analytics modules, and partner ecosystems to healthcare providers seeking end-to-end diabetes management solutions.